BRAFTOVI® Adverse Reactions

(encorafenib)

6 ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling:

•
New Primary Malignancies [see Warnings and Precautions (5.1)]
•
Tumor Promotion in BRAF Wild-Type Tumors [see Warnings and Precautions (5.2)]
•
Cardiomyopathy [see Warnings and Precautions (5.3)]
•
Hepatotoxicity [see Warnings and Precautions (5.4)]
•
Hemorrhage [see Warnings and Precautions (5.5)]
•
Uveitis [see Warnings and Precautions (5.6)]
•
QT Prolongation [see Warnings and Precautions (5.7)]
•
Embryo-Fetal Toxicity [see Warnings and Precautions (5.8)]
•
Risks Associated with BRAFTOVI as a Single Agent [see Warnings and Precautions (5.9)]
•
Risks Associated with Combination Treatment [see Warnings and Precautions (5.10)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma

The safety of BRAFTOVI in combination with binimetinib is described in 192 patients with BRAF V600 mutation-positive unresectable or metastatic melanoma who received BRAFTOVI (450 mg once daily) in combination with binimetinib (45 mg twice daily) in a randomized open-label, active-controlled trial (COLUMBUS).

The COLUMBUS trial [see Clinical Studies (14.1)] excluded patients with a history of Gilbert's syndrome, abnormal left ventricular ejection fraction, prolonged QTc (>480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of exposure was 11.8 months for patients treated with BRAFTOVI in combination with binimetinib and 6.2 months for patients treated with vemurafenib.

The most common (≥25%) adverse reactions in patients receiving BRAFTOVI in combination with binimetinib were fatigue, nausea, vomiting, abdominal pain, and arthralgia.

Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 30% of patients receiving BRAFTOVI in combination with binimetinib; the most common were nausea (7%), vomiting (7%), and pyrexia (4%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 14% of patients receiving BRAFTOVI in combination with binimetinib; the most common were arthralgia (2%), fatigue (2%), and nausea (2%). Five percent (5%) of patients receiving BRAFTOVI in combination with binimetinib experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI; the most common were hemorrhage in 2% and headache in 1% of patients.

Table 5 and Table 6 present adverse drug reactions and laboratory abnormalities, respectively, identified in COLUMBUS. The COLUMBUS trial was not designed to demonstrate a statistically significant difference in adverse reaction rates for BRAFTOVI in combination with binimetinib, as compared to vemurafenib, for any specific adverse reaction listed in Table 5.

Table 5: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Binimetinib in COLUMBUS*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Grade 4 adverse reactions limited to fatigue (n=1), pruritus (n=1), and rash (n=1) in the BRAFTOVI with binimetinib arm.
‡
Represents a composite of multiple, related preferred terms.

Adverse Reaction

BRAFTOVI

with binimetinib
N=192

Vemurafenib
N=186

All Grades
(%)

Grades 3 and 4†
(%)

All Grades
(%)

Grades 3 and 4
(%)

General Disorders and Administration Site Conditions

    Fatigue‡

43

3

46

6

    Pyrexia‡

18

4

30

0

Gastrointestinal Disorders

    Nausea

41

2

34

2

    Vomiting‡

30

2

16

1

    Abdominal pain‡

28

4

16

1

    Constipation

22

0

6

1

Musculoskeletal and Connective Tissue Disorders

    Arthralgia‡

26

1

46

6

    Myopathy‡

23

0

22

1

    Pain in extremity

11

1

13

1

Skin and Subcutaneous Tissue Disorders

    Hyperkeratosis‡

23

1

49

1

    Rash‡

22

1

53

13

    Dry skin‡

16

0

26

0

    Alopecia‡

14

0

38

0

    Pruritus‡

13

1

21

1

Nervous System Disorders

    Headache‡

22

2

20

1

    Dizziness‡

15

3

4

0

    Peripheral neuropathy‡

12

1

13

2

Vascular Disorders

    Hemorrhage‡

19

3

9

2

BRAFTOVI when used as a single agent increases the risk of certain adverse reactions compared to BRAFTOVI in combination with binimetinib. In patients receiving BRAFTOVI 300 mg orally once daily as a single agent, the following adverse reactions were observed at a higher rate (≥5%) compared to patients receiving BRAFTOVI in combination with binimetinib: palmar-plantar erythrodysesthesia syndrome (51% vs. 7%), hyperkeratosis (57% vs. 23%), dry skin (38% vs. 16%), erythema (16% vs. 7%), rash (41% vs. 22%), alopecia (56% vs. 14%), pruritus (31% vs. 13%), arthralgia (44% vs. 26%), myopathy (33% vs. 23%), back pain (15% vs. 9%), dysgeusia (13% vs. 6%), and acneiform dermatitis (8% vs. 3%).

Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with binimetinib were:

Nervous system disorders: Facial paresis

Gastrointestinal disorders: Pancreatitis

Skin and subcutaneous tissue disorders: Panniculitis, Photosensitivity

Immune system disorders: Drug hypersensitivity

Table 6: Laboratory Abnormalities Occurring in ≥10% (All Grades) of Patients Receiving BRAFTOVI in Combination with Binimetinib in COLUMBUS*
*
Grades per National Cancer Institute CTCAE v4.03.

Laboratory Abnormality

BRAFTOVI

with binimetinib*

N=192

Vemurafenib*

N=186

All Grades

(%)

Grades 3 and 4

(%)

All Grades

(%)

Grades 3 and 4

(%)

Hematology

    Anemia

36

3.6

34

2.2

    Leukopenia

13

0

10

0.5

    Lymphopenia

13

2.1

30

7

    Neutropenia

13

3.1

4.8

0.5

Chemistry

    Increased Creatinine

93

3.6

92

1.1

    Increased Gamma Glutamyl Transferase

45

11

34

4.8

    Increased ALT

29

6

27

2.2

    Increased AST

27

2.6

24

1.6

    Hyperglycemia

28

5

20

2.7

    Increased Alkaline Phosphatase

21

0.5

35

2.2

    Hyponatremia

18

3.6

15

0.5

    Hypermagnesemia

10

1.0

26

0.5

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (mCRC) in combination with Cetuximab and mFOLFOX6

The safety of BRAFTOVI 300 mg once daily in combination with cetuximab (500 mg/m2 every 2 weeks) and mFOLFOX6 was evaluated in 231 patients with BRAF V600E mutation-positive metastatic CRC in a randomized, open-label, active-controlled trial (BREAKWATER) [see Clinical Studies (14.2)]. BREAKWATER excluded patients with pancreatitis, leptomeningeal disease, chronic inflammatory bowel disease requiring medical intervention, as well as clinically significant cardiovascular diseases [e.g., myocardial infarction, acute coronary syndromes, NYHA Class ≥II congestive heart failure, prolonged QTcF interval (≥480 ms), history of prolonged QT syndrome] and active infectious conditions.

Among patients who received BRAFTOVI, 54% were exposed for 6 months or longer and 18% were exposed for one year or longer.

Serious adverse reactions occurred in 38% of patients who received BRAFTOVI in combination with cetuximab and mFOLFOX6. Serious adverse reactions in >3% of patients included intestinal obstruction and pyrexia (3.5% each).

Fatal gastrointestinal perforation occurred in 0.9% of patients who received BRAFTOVI in combination with cetuximab and mFOLFOX6.

Permanent discontinuation of BRAFTOVI due to an adverse reaction occurred in 12% of patients. Adverse reactions which resulted in permanent discontinuation of BRAFTOVI in ≥1% of patients included increased lipase.

Dosage interruptions of BRAFTOVI due to an adverse reaction occurred in 57% of patients. Adverse reactions which required dosage interruption in ≥5% included decreased neutrophil count, pyrexia, and anemia.

Dose reductions of BRAFTOVI due to an adverse reaction occurred in 22% of patients. Adverse reactions leading to dose reductions of BRAFTOVI in ≥2% of patients included increased lipase, nausea, and vomiting.

The most common (≥25%) adverse reactions of BRAFTOVI when used in combination with cetuximab and mFOLFOX6 were peripheral neuropathy, nausea, fatigue, rash, diarrhea, decreased appetite, vomiting, hemorrhage, abdominal pain, and pyrexia.

The most common Grade 3 or 4 laboratory abnormalities (≥10%) of BRAFTOVI when used in combination with cetuximab and mFOLFOX6 were increased lipase, decreased neutrophil count, decreased hemoglobin, decreased white blood cell count, and increased glucose.

Table 7 and Table 8 present adverse drug reactions and laboratory abnormalities, respectively, identified in BREAKWATER.

Table 7: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Cetuximab and mFOLFOX6 in BREAKWATER*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Represents multiple related terms.

Adverse Reaction

BRAFTOVI

with cetuximab and mFOLFOX6

N=231

mFOLFOX6 ± bevacizumab

or

FOLFOXIRI ± bevacizumab

or

CAPOX ± bevacizumab

N=228

All Grades

(%)

Grade 3 or 4

(%)

All Grades

(%)

Grade 3 or 4

(%)

Nervous System Disorders

    Peripheral neuropathy†

62

15

53

6

    Headache

13

<1

7

0

    Dysgeusia

12

0

14

0

    Neurotoxicity

11

5

8

0

Gastrointestinal Disorders

    Nausea

51

3

48

3

    Diarrhea

34

1

47

4

    Vomiting

33

4

21

2

    Abdominal pain†

26

4

27

1

    Constipation

20

<1

19

<1

General Disorders and Administration Site Conditions

    Fatigue†

49

7

38

4

    Pyrexia†

26

2

14

<1

Metabolism and Nutrition Disorders

    Decreased appetite

33

2

25

1

Musculoskeletal and Connective Tissue Disorders

    Arthralgia†

23

1

4

0

    Myopathy†

14

0

7

<1

Skin and Subcutaneous Tissue Disorders

    Rash†

31

1

4

0

    Alopecia

21

0

10

0

    Dry skin†

17

0

4

0

    Dermatitis acneiform†

17

1

1

0

    Skin hyperpigmentation

17

0

2

0

    Pruritus

11

0

3

<1

Vascular Disorders

    Hemorrhage†

30

3

18

1

Psychiatric Disorder

Insomnia†

11

0

7

0

Table 8: Laboratory Abnormalities Occurring in ≥20% (All Grades) of Patients Receiving BRAFTOVI in Combination with Cetuximab and mFOLFOX6 in BREAKWATER*
*
Grades per National Cancer Institute CTCAE v4.03.
†
The denominator used to calculate the rate varied from 220 to 227 based on the number of patients with a baseline and at least one post-treatment value.

Laboratory Abnormality†

BRAFTOVI

with cetuximab and mFOLFOX6

mFOLFOX6 ± bevacizumab

or

FOLFOXIRI ± bevacizumab

or

CAPOX ± bevacizumab

All Grades

(%)

Grade 3 or 4

(%)

All Grades

(%)

Grade 3 or 4

(%)

Hematology

   Neutrophil count decreased

63

36

60

34

   White blood cell decreased

62

12

54

7

   Hemoglobin decreased

60

13

47

5

   Platelet count decreased

60

1

50

2

   Activated partial thromboplastin time prolonged

57

3

38

1

   INR increased

39

1

20

1

Chemistry

   Lipase increased

82

51

54

25

   Creatinine increased

64

1

67

1

   Glucose increased

49

11

35

2

   Alanine aminotransferase increased

38

1

40

2

   Albumin decreased

36

0

24

1

   Aspartate aminotransferase increased

36

1

35

2

   Potassium decreased

33

4

19

4

   Alkaline phosphatase increased

31

2

31

1

   Calcium decreased

24

4

16

2

   Magnesium decreased

23

1

11

1

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)

The safety of BRAFTOVI 300 mg once daily in combination with cetuximab (400 mg/m2 initial dose, followed by 250 mg/m2 weekly) was evaluated in 216 patients with BRAF V600E mutation-positive metastatic CRC in a randomized, open-label, active-controlled trial (BEACON CRC). The BEACON CRC trial [see Clinical Studies (14.3)] excluded patients with a history of Gilbert's syndrome, abnormal left ventricular ejection fraction, prolonged QTc (>480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of exposure was 4.4 months for patients treated with BRAFTOVI in combination with cetuximab and 1.6 months for patients treated with either irinotecan or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI) in combination with cetuximab.

The most common (≥25%) adverse reactions in patients receiving BRAFTOVI in combination with cetuximab were fatigue, nausea, diarrhea, dermatitis acneiform, abdominal pain, decreased appetite, arthralgia, and rash.

Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 33% of patients receiving BRAFTOVI in combination with cetuximab; the most common were vomiting (4%), fatigue (4%), nausea (4%), pyrexia (3%), and diarrhea (3%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 9% of patients receiving BRAFTOVI in combination with cetuximab; the most common were fatigue (2%), arthralgia (2%), and peripheral neuropathy (2%). Ten percent (10%) of patients receiving BRAFTOVI in combination with cetuximab experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI. None of the adverse reactions leading to permanent discontinuation of BRAFTOVI occurred in more than one patient (>0.5%).

Table 9 and Table 10 present adverse drug reactions and laboratory abnormalities, respectively, identified in BEACON CRC.

Table 9: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Cetuximab in BEACON CRC*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Grade 4-5 adverse reactions in the BRAFTOVI with cetuximab arm were limited to Grade 5 hemorrhage (n=1).
‡
Represents a composite of multiple, related preferred terms.

Adverse Reaction

BRAFTOVI

with cetuximab

N=216

Irinotecan with cetuximab or FOLFIRI with cetuximab

N=193

All Grades

(%)

≥ Grade 3†

(%)

All Grades

(%)

≥ Grade 3

(%)

General Disorders and Administration Site Conditions

    Fatigue‡

51

7

50

8

    Pyrexia‡

17

1

15

1

Gastrointestinal Disorders

    Nausea

34

1

41

1

    Diarrhea‡

33

2

48

10

    Abdominal pain‡

30

4

32

5

    Vomiting

21

1

29

3

    Constipation

15

0

18

1

Metabolism and Nutrition Disorders

    Decreased appetite

27

1

27

3

Musculoskeletal and Connective Tissue Disorders

    Arthralgia‡

27

1

3

0

    Myopathy‡

15

1

4

0

    Pain in extremity

10

0

1

0

Skin and Subcutaneous Tissue Disorders

    Dermatitis acneiform‡

32

1

43

3

    Rash‡

26

0

26

2

    Pruritus‡

14

0

6

0

    Melanocytic nevus

14

0

0

0

    Dry skin‡

13

0

12

1

Nervous System Disorders

    Headache‡

20

0

3

0

    Peripheral neuropathy‡

12

1

6

0

Vascular Disorders

    Hemorrhage‡

19

2

9

0

Psychiatric Disorders

    Insomnia‡

13

0

6

0

Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with cetuximab were:

Gastrointestinal disorders: Pancreatitis

Table 10: Laboratory Abnormalities Occurring in ≥10% (All Grades) of Patients Receiving BRAFTOVI in Combination with Cetuximab in BEACON CRC*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Based on the number of patients with available baseline and at least one on-treatment laboratory test.

Laboratory Abnormality†

BRAFTOVI

with cetuximab

Irinotecan with cetuximab or FOLFIRI with cetuximab

All Grades
(%)

Grades 3 and 4
(%)

All Grades
(%)

Grades 3 and 4
(%)

Hematology

    Anemia

34

4

48

5

    Lymphopenia

24

7

35

5

    Increased Activated Partial Thromboplastin Time

13

1

7

1

Chemistry

    Hypomagnesemia

19

0

22

1

    Increased Alkaline Phosphatase

18

4

30

7

    Increased ALT

17

0

29

3

    Increased AST

15

1

22

2

    Hypokalemia

12

3

32

5

    Hyponatremia

11

2

13

2

BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

The safety of BRAFTOVI in combination with binimetinib was evaluated in 98 patients with BRAF V600E mutation-positive metastatic NSCLC who received BRAFTOVI (450 mg once daily) in combination with binimetinib (45 mg twice daily) in an open-label, single-arm trial (PHAROS).

The PHAROS trial [see Clinical Studies (14.4)] excluded patients with abnormal left ventricular ejection fraction, prolonged QTc (>480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of treatment for BRAFTOVI and binimetinib was 9.2 and 8.4 months, respectively.

The most common (≥25%) adverse reactions in patients receiving BRAFTOVI were fatigue, nausea, diarrhea, musculoskeletal pain, vomiting, abdominal pain, visual impairment, constipation, dyspnea, rash, and cough.

Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 59% of patients receiving BRAFTOVI; the most common (≥5%) were diarrhea (17%); nausea (13%); musculoskeletal pain, fatigue (8% each); AST increased (7%); ALT increased, anemia, hemorrhage, vomiting (6% each); and acute kidney injury (5%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 30% of patients receiving BRAFTOVI; the most common (≥5%) were diarrhea, nausea (8% each); AST increased and fatigue (5% each). A total of 16% of patients receiving BRAFTOVI experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI; the most common (≥2%) were diarrhea, musculoskeletal pain (3.1% each); fatigue, rash, nausea, visual impairment, and vomiting (2% each). None of the other adverse reactions leading to permanent discontinuation of BRAFTOVI occurred in more than 1 patient.

Serious adverse reactions occurred in 38% of patients who received BRAFTOVI in combination with binimetinib. Serious adverse reactions occurring in ≥2% of patients were hemorrhage (6%); diarrhea (4.1%); anemia, dyspnea, pneumonia (3.1% each); arrhythmia, device related infection, edema, myocardial infarction, and pleural effusion (2% each). Fatal adverse reactions occurred in 2% of patients who received BRAFTOVI (450 mg once daily) in combination with binimetinib, including intracranial hemorrhage and myocardial infarction (1% each).

Table 11 and Table 12 present adverse drug reactions and laboratory abnormalities, respectively, identified in PHAROS.

Table 11: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Binimetinib in PHAROS*
*
Grades per National Cancer Institute CTCAE v4.03.
†
One Grade 5 adverse reaction of hemorrhage occurred.
‡
Fatigue includes fatigue, asthenia.
§
Edema includes edema peripheral, generalized edema, swelling, localized edema, face edema.
Diarrhea includes diarrhea, colitis.
#
Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, epigastric discomfort.
Þ
Visual impairment includes vision blurred, visual impairment, vitreous floaters, photophobia, visual acuity reduced, photopsia.
ß
Musculoskeletal pain includes back pain, arthralgia, pain in extremity, myalgia, musculoskeletal chest pain, noncardiac chest pain, neck pain.
à
Rash includes rash, rash macular, rash maculo-papular, rash papular, rash pustular, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, eczema, skin exfoliation.
è
Pruritis includes pruritus, pruritus genital.
ð
Dyspnea includes dyspnea, dyspnea exertional.
ø
Cough includes cough, productive cough.
ý
Dizziness includes dizziness, balance disorder.
£
Hemorrhage includes anal hemorrhage, hemothorax, gastrointestinal hemorrhage, hematochezia, hematuria, hemoptysis, hemorrhage intracranial, hyphema, small intestinal hemorrhage, upper gastrointestinal hemorrhage, vaginal hemorrhage.
¥
Left ventricular dysfunction/cardiomyopathy includes ejection fraction decreased, cardiac failure, cardiac failure congestive.

Adverse Reaction

BRAFTOVI

with binimetinib
N=98

All Grades

(%)

Grades 3 and 4†

(%)

General Disorders and Administration Site Conditions

    Fatigue‡

61

8

    Edema§

23

1

    Pyrexia

22

0

Gastrointestinal Disorders

    Nausea

58

3.1

    Diarrhea

52

7

    Vomiting

37

1

    Abdominal pain#

32

1

    Constipation

27

0

Eye Disorders

    Visual impairmentÞ

29

2

Musculoskeletal and Connective Tissue Disorders

    Musculoskeletal painß

48

4.1

Skin and Subcutaneous Tissue Disorders

    Rashà

27

3.1

    Pruritisè

16

0

    Dry skin

13

0

    Alopecia

12

0

Respiratory, Thoracic and Mediastinal Disorders

    Dyspneað

27

8

    Coughø

26

0

Nervous System Disorders

    Dizzinessý

17

1

    Headache

11

0

Metabolism and Nutrition Disorders

    Decreased appetite

14

1

Vascular Disorders

    Hemorrhage†£

12

4.1

    Hypertension

10

5

Cardiac Disorders

    Left ventricular dysfunction/cardiomyopathy¥

11

1

Investigations

    Weight increased

11

1

Psychiatric Disorders

    Insomnia

10

0

Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with binimetinib were:

Nervous system disorders: Peripheral neuropathy, Dysgeusia, Facial paresis

Gastrointestinal disorders: Pancreatitis

Skin and subcutaneous tissue disorders: Hyperkeratosis, Erythema, Photosensitivity

Immune system disorders: Drug hypersensitivity

Table 12: Laboratory Abnormalities Occurring in ≥10% (All Grades) of Patients Receiving BRAFTOVI with Binimetinib*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Based on the number of patients with available baseline and at least one on-treatment laboratory test.

Laboratory Abnormality†

BRAFTOVI with binimetinib

All Grades

(%)

Grades 3 and 4

(%)

Hematology

   Anemia

47

11

   Lymphopenia

24

6

   Thrombocytopenia

20

1.1

   Leukopenia

12

0

   Neutropenia

12

1.1

Chemistry

   Increased creatinine

91

3.2

   Hyperglycemia

48

6

   Increased creatine kinase

41

3.3

   Lipase increased

40

14

   Increased ALT

34

9

   Hypoalbuminemia

32

0

   Increased AST

31

10

   Increased alkaline phosphatase

31

3.2

   Hyperkalemia

31

2.1

   Hyponatremia

26

11

   Serum amylase increased

22

1.1

   Hypocalcemia

12

2.1

Find BRAFTOVI® medical information:

Find BRAFTOVI® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

BRAFTOVI® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

The following adverse reactions are described elsewhere in the labeling:

•
New Primary Malignancies [see Warnings and Precautions (5.1)]
•
Tumor Promotion in BRAF Wild-Type Tumors [see Warnings and Precautions (5.2)]
•
Cardiomyopathy [see Warnings and Precautions (5.3)]
•
Hepatotoxicity [see Warnings and Precautions (5.4)]
•
Hemorrhage [see Warnings and Precautions (5.5)]
•
Uveitis [see Warnings and Precautions (5.6)]
•
QT Prolongation [see Warnings and Precautions (5.7)]
•
Embryo-Fetal Toxicity [see Warnings and Precautions (5.8)]
•
Risks Associated with BRAFTOVI as a Single Agent [see Warnings and Precautions (5.9)]
•
Risks Associated with Combination Treatment [see Warnings and Precautions (5.10)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma

The safety of BRAFTOVI in combination with binimetinib is described in 192 patients with BRAF V600 mutation-positive unresectable or metastatic melanoma who received BRAFTOVI (450 mg once daily) in combination with binimetinib (45 mg twice daily) in a randomized open-label, active-controlled trial (COLUMBUS).

The COLUMBUS trial [see Clinical Studies (14.1)] excluded patients with a history of Gilbert's syndrome, abnormal left ventricular ejection fraction, prolonged QTc (>480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of exposure was 11.8 months for patients treated with BRAFTOVI in combination with binimetinib and 6.2 months for patients treated with vemurafenib.

The most common (≥25%) adverse reactions in patients receiving BRAFTOVI in combination with binimetinib were fatigue, nausea, vomiting, abdominal pain, and arthralgia.

Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 30% of patients receiving BRAFTOVI in combination with binimetinib; the most common were nausea (7%), vomiting (7%), and pyrexia (4%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 14% of patients receiving BRAFTOVI in combination with binimetinib; the most common were arthralgia (2%), fatigue (2%), and nausea (2%). Five percent (5%) of patients receiving BRAFTOVI in combination with binimetinib experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI; the most common were hemorrhage in 2% and headache in 1% of patients.

Table 5 and Table 6 present adverse drug reactions and laboratory abnormalities, respectively, identified in COLUMBUS. The COLUMBUS trial was not designed to demonstrate a statistically significant difference in adverse reaction rates for BRAFTOVI in combination with binimetinib, as compared to vemurafenib, for any specific adverse reaction listed in Table 5.

Table 5: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Binimetinib in COLUMBUS*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Grade 4 adverse reactions limited to fatigue (n=1), pruritus (n=1), and rash (n=1) in the BRAFTOVI with binimetinib arm.
‡
Represents a composite of multiple, related preferred terms.

Adverse Reaction

BRAFTOVI

with binimetinib
N=192

Vemurafenib
N=186

All Grades
(%)

Grades 3 and 4†
(%)

All Grades
(%)

Grades 3 and 4
(%)

General Disorders and Administration Site Conditions

    Fatigue‡

43

3

46

6

    Pyrexia‡

18

4

30

0

Gastrointestinal Disorders

    Nausea

41

2

34

2

    Vomiting‡

30

2

16

1

    Abdominal pain‡

28

4

16

1

    Constipation

22

0

6

1

Musculoskeletal and Connective Tissue Disorders

    Arthralgia‡

26

1

46

6

    Myopathy‡

23

0

22

1

    Pain in extremity

11

1

13

1

Skin and Subcutaneous Tissue Disorders

    Hyperkeratosis‡

23

1

49

1

    Rash‡

22

1

53

13

    Dry skin‡

16

0

26

0

    Alopecia‡

14

0

38

0

    Pruritus‡

13

1

21

1

Nervous System Disorders

    Headache‡

22

2

20

1

    Dizziness‡

15

3

4

0

    Peripheral neuropathy‡

12

1

13

2

Vascular Disorders

    Hemorrhage‡

19

3

9

2

BRAFTOVI when used as a single agent increases the risk of certain adverse reactions compared to BRAFTOVI in combination with binimetinib. In patients receiving BRAFTOVI 300 mg orally once daily as a single agent, the following adverse reactions were observed at a higher rate (≥5%) compared to patients receiving BRAFTOVI in combination with binimetinib: palmar-plantar erythrodysesthesia syndrome (51% vs. 7%), hyperkeratosis (57% vs. 23%), dry skin (38% vs. 16%), erythema (16% vs. 7%), rash (41% vs. 22%), alopecia (56% vs. 14%), pruritus (31% vs. 13%), arthralgia (44% vs. 26%), myopathy (33% vs. 23%), back pain (15% vs. 9%), dysgeusia (13% vs. 6%), and acneiform dermatitis (8% vs. 3%).

Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with binimetinib were:

Nervous system disorders: Facial paresis

Gastrointestinal disorders: Pancreatitis

Skin and subcutaneous tissue disorders: Panniculitis, Photosensitivity

Immune system disorders: Drug hypersensitivity

Table 6: Laboratory Abnormalities Occurring in ≥10% (All Grades) of Patients Receiving BRAFTOVI in Combination with Binimetinib in COLUMBUS*
*
Grades per National Cancer Institute CTCAE v4.03.

Laboratory Abnormality

BRAFTOVI

with binimetinib*

N=192

Vemurafenib*

N=186

All Grades

(%)

Grades 3 and 4

(%)

All Grades

(%)

Grades 3 and 4

(%)

Hematology

    Anemia

36

3.6

34

2.2

    Leukopenia

13

0

10

0.5

    Lymphopenia

13

2.1

30

7

    Neutropenia

13

3.1

4.8

0.5

Chemistry

    Increased Creatinine

93

3.6

92

1.1

    Increased Gamma Glutamyl Transferase

45

11

34

4.8

    Increased ALT

29

6

27

2.2

    Increased AST

27

2.6

24

1.6

    Hyperglycemia

28

5

20

2.7

    Increased Alkaline Phosphatase

21

0.5

35

2.2

    Hyponatremia

18

3.6

15

0.5

    Hypermagnesemia

10

1.0

26

0.5

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (mCRC) in combination with Cetuximab and mFOLFOX6

The safety of BRAFTOVI 300 mg once daily in combination with cetuximab (500 mg/m2 every 2 weeks) and mFOLFOX6 was evaluated in 231 patients with BRAF V600E mutation-positive metastatic CRC in a randomized, open-label, active-controlled trial (BREAKWATER) [see Clinical Studies (14.2)]. BREAKWATER excluded patients with pancreatitis, leptomeningeal disease, chronic inflammatory bowel disease requiring medical intervention, as well as clinically significant cardiovascular diseases [e.g., myocardial infarction, acute coronary syndromes, NYHA Class ≥II congestive heart failure, prolonged QTcF interval (≥480 ms), history of prolonged QT syndrome] and active infectious conditions.

Among patients who received BRAFTOVI, 54% were exposed for 6 months or longer and 18% were exposed for one year or longer.

Serious adverse reactions occurred in 38% of patients who received BRAFTOVI in combination with cetuximab and mFOLFOX6. Serious adverse reactions in >3% of patients included intestinal obstruction and pyrexia (3.5% each).

Fatal gastrointestinal perforation occurred in 0.9% of patients who received BRAFTOVI in combination with cetuximab and mFOLFOX6.

Permanent discontinuation of BRAFTOVI due to an adverse reaction occurred in 12% of patients. Adverse reactions which resulted in permanent discontinuation of BRAFTOVI in ≥1% of patients included increased lipase.

Dosage interruptions of BRAFTOVI due to an adverse reaction occurred in 57% of patients. Adverse reactions which required dosage interruption in ≥5% included decreased neutrophil count, pyrexia, and anemia.

Dose reductions of BRAFTOVI due to an adverse reaction occurred in 22% of patients. Adverse reactions leading to dose reductions of BRAFTOVI in ≥2% of patients included increased lipase, nausea, and vomiting.

The most common (≥25%) adverse reactions of BRAFTOVI when used in combination with cetuximab and mFOLFOX6 were peripheral neuropathy, nausea, fatigue, rash, diarrhea, decreased appetite, vomiting, hemorrhage, abdominal pain, and pyrexia.

The most common Grade 3 or 4 laboratory abnormalities (≥10%) of BRAFTOVI when used in combination with cetuximab and mFOLFOX6 were increased lipase, decreased neutrophil count, decreased hemoglobin, decreased white blood cell count, and increased glucose.

Table 7 and Table 8 present adverse drug reactions and laboratory abnormalities, respectively, identified in BREAKWATER.

Table 7: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Cetuximab and mFOLFOX6 in BREAKWATER*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Represents multiple related terms.

Adverse Reaction

BRAFTOVI

with cetuximab and mFOLFOX6

N=231

mFOLFOX6 ± bevacizumab

or

FOLFOXIRI ± bevacizumab

or

CAPOX ± bevacizumab

N=228

All Grades

(%)

Grade 3 or 4

(%)

All Grades

(%)

Grade 3 or 4

(%)

Nervous System Disorders

    Peripheral neuropathy†

62

15

53

6

    Headache

13

<1

7

0

    Dysgeusia

12

0

14

0

    Neurotoxicity

11

5

8

0

Gastrointestinal Disorders

    Nausea

51

3

48

3

    Diarrhea

34

1

47

4

    Vomiting

33

4

21

2

    Abdominal pain†

26

4

27

1

    Constipation

20

<1

19

<1

General Disorders and Administration Site Conditions

    Fatigue†

49

7

38

4

    Pyrexia†

26

2

14

<1

Metabolism and Nutrition Disorders

    Decreased appetite

33

2

25

1

Musculoskeletal and Connective Tissue Disorders

    Arthralgia†

23

1

4

0

    Myopathy†

14

0

7

<1

Skin and Subcutaneous Tissue Disorders

    Rash†

31

1

4

0

    Alopecia

21

0

10

0

    Dry skin†

17

0

4

0

    Dermatitis acneiform†

17

1

1

0

    Skin hyperpigmentation

17

0

2

0

    Pruritus

11

0

3

<1

Vascular Disorders

    Hemorrhage†

30

3

18

1

Psychiatric Disorder

Insomnia†

11

0

7

0

Table 8: Laboratory Abnormalities Occurring in ≥20% (All Grades) of Patients Receiving BRAFTOVI in Combination with Cetuximab and mFOLFOX6 in BREAKWATER*
*
Grades per National Cancer Institute CTCAE v4.03.
†
The denominator used to calculate the rate varied from 220 to 227 based on the number of patients with a baseline and at least one post-treatment value.

Laboratory Abnormality†

BRAFTOVI

with cetuximab and mFOLFOX6

mFOLFOX6 ± bevacizumab

or

FOLFOXIRI ± bevacizumab

or

CAPOX ± bevacizumab

All Grades

(%)

Grade 3 or 4

(%)

All Grades

(%)

Grade 3 or 4

(%)

Hematology

   Neutrophil count decreased

63

36

60

34

   White blood cell decreased

62

12

54

7

   Hemoglobin decreased

60

13

47

5

   Platelet count decreased

60

1

50

2

   Activated partial thromboplastin time prolonged

57

3

38

1

   INR increased

39

1

20

1

Chemistry

   Lipase increased

82

51

54

25

   Creatinine increased

64

1

67

1

   Glucose increased

49

11

35

2

   Alanine aminotransferase increased

38

1

40

2

   Albumin decreased

36

0

24

1

   Aspartate aminotransferase increased

36

1

35

2

   Potassium decreased

33

4

19

4

   Alkaline phosphatase increased

31

2

31

1

   Calcium decreased

24

4

16

2

   Magnesium decreased

23

1

11

1

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)

The safety of BRAFTOVI 300 mg once daily in combination with cetuximab (400 mg/m2 initial dose, followed by 250 mg/m2 weekly) was evaluated in 216 patients with BRAF V600E mutation-positive metastatic CRC in a randomized, open-label, active-controlled trial (BEACON CRC). The BEACON CRC trial [see Clinical Studies (14.3)] excluded patients with a history of Gilbert's syndrome, abnormal left ventricular ejection fraction, prolonged QTc (>480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of exposure was 4.4 months for patients treated with BRAFTOVI in combination with cetuximab and 1.6 months for patients treated with either irinotecan or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI) in combination with cetuximab.

The most common (≥25%) adverse reactions in patients receiving BRAFTOVI in combination with cetuximab were fatigue, nausea, diarrhea, dermatitis acneiform, abdominal pain, decreased appetite, arthralgia, and rash.

Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 33% of patients receiving BRAFTOVI in combination with cetuximab; the most common were vomiting (4%), fatigue (4%), nausea (4%), pyrexia (3%), and diarrhea (3%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 9% of patients receiving BRAFTOVI in combination with cetuximab; the most common were fatigue (2%), arthralgia (2%), and peripheral neuropathy (2%). Ten percent (10%) of patients receiving BRAFTOVI in combination with cetuximab experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI. None of the adverse reactions leading to permanent discontinuation of BRAFTOVI occurred in more than one patient (>0.5%).

Table 9 and Table 10 present adverse drug reactions and laboratory abnormalities, respectively, identified in BEACON CRC.

Table 9: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Cetuximab in BEACON CRC*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Grade 4-5 adverse reactions in the BRAFTOVI with cetuximab arm were limited to Grade 5 hemorrhage (n=1).
‡
Represents a composite of multiple, related preferred terms.

Adverse Reaction

BRAFTOVI

with cetuximab

N=216

Irinotecan with cetuximab or FOLFIRI with cetuximab

N=193

All Grades

(%)

≥ Grade 3†

(%)

All Grades

(%)

≥ Grade 3

(%)

General Disorders and Administration Site Conditions

    Fatigue‡

51

7

50

8

    Pyrexia‡

17

1

15

1

Gastrointestinal Disorders

    Nausea

34

1

41

1

    Diarrhea‡

33

2

48

10

    Abdominal pain‡

30

4

32

5

    Vomiting

21

1

29

3

    Constipation

15

0

18

1

Metabolism and Nutrition Disorders

    Decreased appetite

27

1

27

3

Musculoskeletal and Connective Tissue Disorders

    Arthralgia‡

27

1

3

0

    Myopathy‡

15

1

4

0

    Pain in extremity

10

0

1

0

Skin and Subcutaneous Tissue Disorders

    Dermatitis acneiform‡

32

1

43

3

    Rash‡

26

0

26

2

    Pruritus‡

14

0

6

0

    Melanocytic nevus

14

0

0

0

    Dry skin‡

13

0

12

1

Nervous System Disorders

    Headache‡

20

0

3

0

    Peripheral neuropathy‡

12

1

6

0

Vascular Disorders

    Hemorrhage‡

19

2

9

0

Psychiatric Disorders

    Insomnia‡

13

0

6

0

Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with cetuximab were:

Gastrointestinal disorders: Pancreatitis

Table 10: Laboratory Abnormalities Occurring in ≥10% (All Grades) of Patients Receiving BRAFTOVI in Combination with Cetuximab in BEACON CRC*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Based on the number of patients with available baseline and at least one on-treatment laboratory test.

Laboratory Abnormality†

BRAFTOVI

with cetuximab

Irinotecan with cetuximab or FOLFIRI with cetuximab

All Grades
(%)

Grades 3 and 4
(%)

All Grades
(%)

Grades 3 and 4
(%)

Hematology

    Anemia

34

4

48

5

    Lymphopenia

24

7

35

5

    Increased Activated Partial Thromboplastin Time

13

1

7

1

Chemistry

    Hypomagnesemia

19

0

22

1

    Increased Alkaline Phosphatase

18

4

30

7

    Increased ALT

17

0

29

3

    Increased AST

15

1

22

2

    Hypokalemia

12

3

32

5

    Hyponatremia

11

2

13

2

BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

The safety of BRAFTOVI in combination with binimetinib was evaluated in 98 patients with BRAF V600E mutation-positive metastatic NSCLC who received BRAFTOVI (450 mg once daily) in combination with binimetinib (45 mg twice daily) in an open-label, single-arm trial (PHAROS).

The PHAROS trial [see Clinical Studies (14.4)] excluded patients with abnormal left ventricular ejection fraction, prolonged QTc (>480 ms), uncontrolled hypertension, and history or current evidence of retinal vein occlusion. The median duration of treatment for BRAFTOVI and binimetinib was 9.2 and 8.4 months, respectively.

The most common (≥25%) adverse reactions in patients receiving BRAFTOVI were fatigue, nausea, diarrhea, musculoskeletal pain, vomiting, abdominal pain, visual impairment, constipation, dyspnea, rash, and cough.

Adverse reactions leading to dose interruptions of BRAFTOVI occurred in 59% of patients receiving BRAFTOVI; the most common (≥5%) were diarrhea (17%); nausea (13%); musculoskeletal pain, fatigue (8% each); AST increased (7%); ALT increased, anemia, hemorrhage, vomiting (6% each); and acute kidney injury (5%). Adverse reactions leading to dose reductions of BRAFTOVI occurred in 30% of patients receiving BRAFTOVI; the most common (≥5%) were diarrhea, nausea (8% each); AST increased and fatigue (5% each). A total of 16% of patients receiving BRAFTOVI experienced an adverse reaction that resulted in permanent discontinuation of BRAFTOVI; the most common (≥2%) were diarrhea, musculoskeletal pain (3.1% each); fatigue, rash, nausea, visual impairment, and vomiting (2% each). None of the other adverse reactions leading to permanent discontinuation of BRAFTOVI occurred in more than 1 patient.

Serious adverse reactions occurred in 38% of patients who received BRAFTOVI in combination with binimetinib. Serious adverse reactions occurring in ≥2% of patients were hemorrhage (6%); diarrhea (4.1%); anemia, dyspnea, pneumonia (3.1% each); arrhythmia, device related infection, edema, myocardial infarction, and pleural effusion (2% each). Fatal adverse reactions occurred in 2% of patients who received BRAFTOVI (450 mg once daily) in combination with binimetinib, including intracranial hemorrhage and myocardial infarction (1% each).

Table 11 and Table 12 present adverse drug reactions and laboratory abnormalities, respectively, identified in PHAROS.

Table 11: Adverse Reactions Occurring in ≥10% of Patients Receiving BRAFTOVI in Combination with Binimetinib in PHAROS*
*
Grades per National Cancer Institute CTCAE v4.03.
†
One Grade 5 adverse reaction of hemorrhage occurred.
‡
Fatigue includes fatigue, asthenia.
§
Edema includes edema peripheral, generalized edema, swelling, localized edema, face edema.
Diarrhea includes diarrhea, colitis.
#
Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, epigastric discomfort.
Þ
Visual impairment includes vision blurred, visual impairment, vitreous floaters, photophobia, visual acuity reduced, photopsia.
ß
Musculoskeletal pain includes back pain, arthralgia, pain in extremity, myalgia, musculoskeletal chest pain, noncardiac chest pain, neck pain.
à
Rash includes rash, rash macular, rash maculo-papular, rash papular, rash pustular, dermatitis acneiform, palmar-plantar erythrodysesthesia syndrome, eczema, skin exfoliation.
è
Pruritis includes pruritus, pruritus genital.
ð
Dyspnea includes dyspnea, dyspnea exertional.
ø
Cough includes cough, productive cough.
ý
Dizziness includes dizziness, balance disorder.
£
Hemorrhage includes anal hemorrhage, hemothorax, gastrointestinal hemorrhage, hematochezia, hematuria, hemoptysis, hemorrhage intracranial, hyphema, small intestinal hemorrhage, upper gastrointestinal hemorrhage, vaginal hemorrhage.
¥
Left ventricular dysfunction/cardiomyopathy includes ejection fraction decreased, cardiac failure, cardiac failure congestive.

Adverse Reaction

BRAFTOVI

with binimetinib
N=98

All Grades

(%)

Grades 3 and 4†

(%)

General Disorders and Administration Site Conditions

    Fatigue‡

61

8

    Edema§

23

1

    Pyrexia

22

0

Gastrointestinal Disorders

    Nausea

58

3.1

    Diarrhea

52

7

    Vomiting

37

1

    Abdominal pain#

32

1

    Constipation

27

0

Eye Disorders

    Visual impairmentÞ

29

2

Musculoskeletal and Connective Tissue Disorders

    Musculoskeletal painß

48

4.1

Skin and Subcutaneous Tissue Disorders

    Rashà

27

3.1

    Pruritisè

16

0

    Dry skin

13

0

    Alopecia

12

0

Respiratory, Thoracic and Mediastinal Disorders

    Dyspneað

27

8

    Coughø

26

0

Nervous System Disorders

    Dizzinessý

17

1

    Headache

11

0

Metabolism and Nutrition Disorders

    Decreased appetite

14

1

Vascular Disorders

    Hemorrhage†£

12

4.1

    Hypertension

10

5

Cardiac Disorders

    Left ventricular dysfunction/cardiomyopathy¥

11

1

Investigations

    Weight increased

11

1

Psychiatric Disorders

    Insomnia

10

0

Other clinically important adverse reactions occurring in <10% of patients who received BRAFTOVI in combination with binimetinib were:

Nervous system disorders: Peripheral neuropathy, Dysgeusia, Facial paresis

Gastrointestinal disorders: Pancreatitis

Skin and subcutaneous tissue disorders: Hyperkeratosis, Erythema, Photosensitivity

Immune system disorders: Drug hypersensitivity

Table 12: Laboratory Abnormalities Occurring in ≥10% (All Grades) of Patients Receiving BRAFTOVI with Binimetinib*
*
Grades per National Cancer Institute CTCAE v4.03.
†
Based on the number of patients with available baseline and at least one on-treatment laboratory test.

Laboratory Abnormality†

BRAFTOVI with binimetinib

All Grades

(%)

Grades 3 and 4

(%)

Hematology

   Anemia

47

11

   Lymphopenia

24

6

   Thrombocytopenia

20

1.1

   Leukopenia

12

0

   Neutropenia

12

1.1

Chemistry

   Increased creatinine

91

3.2

   Hyperglycemia

48

6

   Increased creatine kinase

41

3.3

   Lipase increased

40

14

   Increased ALT

34

9

   Hypoalbuminemia

32

0

   Increased AST

31

10

   Increased alkaline phosphatase

31

3.2

   Hyperkalemia

31

2.1

   Hyponatremia

26

11

   Serum amylase increased

22

1.1

   Hypocalcemia

12

2.1
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.